Abstract
Background
Familial apo C-II deficiency is a rare hereditary disorder frequently caused by lipoprotein lipase (LPL) and APOC2 gene mutations. To date, less than 30 patients with familial apo C-II deficiency with 24 different mutations have been identified in the literature. Here, we describe two familial chylomicronemia syndrome cases in infants with two novel mutations of the APOC2 gene.
Case presentation
Case 1, a 46-day-old female, was admitted to our hospital for evaluation due to the lipemic appearance of the blood sample. A clinical examination revealed hepatomegaly and lipemia retinalis. Triglyceride level of 6295 mg/dL was decreased with a strict low-fat diet, medium-chain triglycerides (MCT) oil-rich formula and omega-3 fatty acid supplementation. Due to low adherence to the diet, TG elevation was detected and fresh frozen plasma (10 mL/kg/day) was administered for 2 days. A novel homozygous p.Q25X (c.73C>T) mutation in the APOC2 gene was detected. Case 2, a 10-month-old female patient, referred to our center for the differential diagnosis of hyperlipidemia as her blood sample could not be assessed due to its lipemic appearance. Laboratory examinations showed a TG level of 4520 mg/dL which was reduced with a low-fat diet, MCT oil-rich formula and omega-3 fatty acid supplementation. Hepatosteatosis and splenomegaly were determined using abdominal sonography. A novel homozygous IVS2+6T>G (c.55+6T>G) mutation in the APOC2 gene was identified.
Conclusions
We describe two novel homozygous mutations (p.Q25X [c.73C>T] and IVS2+6T>G [c.55+6T>G]) in the APOC2 gene in infants with hyperchylomicronemia. To the best of our knowledge, Case 1 is the youngest patient with familial apo C-II deficiency in the literature to date.
Acknowledgments
We would like to express our gratitude to the patients’ parents for their understanding and cooperation in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Rahalkar AR, Hegele RA. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab 2008;93:282–94.1802322410.1016/j.ymgme.2007.10.007Search in Google Scholar
2. Nierman MC, Rip J, Twisk J, Meulenberg JJ, Kastelein JJ, et al. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. Neth J Med 2005;63:14–9.15719847Search in Google Scholar
3. Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol 2016;10(1 Suppl):1–43.10.1016/j.jacl.2015.08.002Search in Google Scholar
4. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007;176:1113–20.10.1503/cmaj.06096317420495Search in Google Scholar
5. Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, et al. Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis 2017;267:49–60.10.1016/j.atherosclerosis.2017.10.02529100061Search in Google Scholar
6. Feoli-Fonseca JC, Lévy E, Godard M, Lambert M. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J Pediatr 1998;133:417–23.10.1016/S0022-3476(98)70280-X9738727Search in Google Scholar
7. Wilson CJ, Priore Oliva C, Maggi F, Catapano AL, Calandra S. Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Ann Neurol 2003;53:807–10.1278343010.1002/ana.10598Search in Google Scholar
8. Brown WV, Levy RI, Fredrickson DS. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem 1970;245:6588–94.548277010.1016/S0021-9258(18)62574-8Search in Google Scholar
9. LaRosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970;41:57–62.10.1016/0006-291X(70)90468-75459123Search in Google Scholar
10. Miller NE, Rao SN, Alaupovic P, Noble N, Slack J, et al. Familial apolipoprotein CII deficiency: plasma lipoproteins and apolipoproteins in heterozygous and homozygous subjects and the effects of plasma infusion. Eur J Clin Invest 1981;11:69–76.678343210.1111/j.1365-2362.1981.tb01768.xSearch in Google Scholar
11. Xiong WJ, Li WH, Posner I, Yamamura T, Yamamoto A, et al. No severe bottleneck during human evolution: evidence from two apolipoprotein C-II deficiency alleles. Am J Hum Genet 1991;48:383–9.1990844Search in Google Scholar
12. Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency. Clin Chim Acta 2015;438:148–53.10.1016/j.cca.2014.08.022Search in Google Scholar
13. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, et al.; Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 2012;19:1–12.2212952310.5551/jat.10702Search in Google Scholar
14. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, et al.; Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969–89.10.1210/jc.2011-321322962670Search in Google Scholar
15. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455–63.1256286510.1194/jlr.M200282-JLR200Search in Google Scholar
16. Filippatos TD, Elisaf MS. Recommendations for severe hypertriglyceridemia treatment, are there new strategies? Curr Vasc Pharmacol 2013;12:598–616.10.2174/15701611113119990133Search in Google Scholar
17. Joglekar K, Brannick B, Kadaria D, Sodhi A. Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature. Ther Adv Endocrinol Metab 2017;8:59–65.10.1177/204201881769544928507728Search in Google Scholar
18. Sakurai T, Sakurai A, Vaisman BL, Amar MJ, Liu C, et al. Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther 2016;356:341–53.2657451510.1124/jpet.115.229740Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston